Derivatives of dicarboxylic acid having pharmaceutical properties
AssigneeBayer Aktiengesellschaft
InventorsCristina Alonso-Alija, Markus Heil, Dietmar Flubacher, Paul Naab, Josef Pernerstorfer, Johannes-Peter Stasch, Frank Wunder, Klaus Dembowsky, Elisabeth Perzborn, Elke Stahl
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, pharmaceutical compositions containing them, and methods for using them for treatment of cardiovascular disorders are also disclosed and claimed.
Claims17
A compound of the general formula (I)
- in which
- V is absent, O, NR4, NR4CONR4, NR4CO, NR4SO2, COO, CONR4 or S(O)o,
- in which
- R4, independently of any other radical R4 which may be present, is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or arylalkyl having 7 to 18 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, alkyl, or alkoxy having up to 6 carbon atoms,
- o is 0, 1 or 2,
- Q is absent, straight-chain or branched alkylene, straight-chain or branched alkenediyl or straight-chain or branched alkynediyl, having in each case up to 12 carbon atoms, which may in each case contain one or more groups selected from the group consisting of O, S(O)p, NR5, CO, NR5SO2 and CONR5 and which may be mono- or polysubstituted by halogen, hydroxyl or alkoxy having up to 4 carbon atoms, where optionally any two atoms of the abovementioned chain may be attached to one another forming a three- to eight-membered ring,
- in which
- R5 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, which may be substituted by halogen or alkoxy having up to 4 carbon atoms, and
- p is 0, 1 or 2,
- Y is hydrogen, NR8R9, aryl having 6 to 10 carbon atoms, or straight-chain or branched cycloalkyl having 3 to 8 carbon atoms, wherein the cyclic radicals may in each case be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched halogenoalkyl, straight-chain or branched halogenoalkoxy having in each case up to 8 carbon atoms, straight-chain or branched cycloalkyl having 3 to 8 carbon atoms, halogen, hydroxyl, CN, SR6, NO2, NR8R9, NR7COR10, NR7CONR7R10 or CONR11R12,
- in which
- R6 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, straight-chain or branched halogenoalkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R7 independently of any other radical R7 which may be present is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R8, R9, R11 and R12 independently of one another are hydrogen, straight-chain or branched alkyl, straight-chain or branched alkenyl having up to 8 carbon atoms, aryl having 6 to 10 carbon atoms, arylalkyl having 8 to 18 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO2R13, wherein the aryl radical for its part may be mono- or polysubstituted by halogen, hydroxyl, CN, NO2, NH2, NHCOR7, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms,
- and wherein
- R13 is straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, CN, NO2, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms,
- R10 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, or cycloalkyl having 3 to 8 carbon atoms, which may furthermore optionally be substituted by halogen, hydroxyl, CN, NO2, NH2, NHCOR7, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms;
- and/or the cyclic radicals in Y may in each case be mono- to trisubstituted by aryl having 6 to 10 carbon atoms, which may be attached directly or via a group O, S, SO, SO2, NR7, SO2NR7, CONR7, straight-chain or branched alkylene, straight-chain or branched alkenediyl, straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulphonylalkyl, straight-chain or branched thioalkyl having in each case up to 8 carbon atoms and which may be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched halogenoalkyl, straight-chain or branched halogenoalkoxy, carbonylalkyl or straight-chain or branched alkenyl having in each case up to 6 carbon atoms, halogen, SR6, CN, NO2, NR8R9, CONR15R16 or NR14COR17,
- in which
- R14is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R15, R16 independently of one another are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or a radical of the formula SO2R18, where the aryl radical for its part may be mono- or polysubstituted by halogen, hydroxyl, CN, NO2, NH2, NHCOR7, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms, in which
- R18 is straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, hydroxyl, CN, NO2, NH2, NHCOR7, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms,
- and
- R17 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, or cycloalkyl having 3 to 8 carbon atoms, which may furthermore optionally be substituted by halogen, hydroxyl, CN, NO2, NH2, NHCOR7, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms;
- and/or the cyclic radicals in Y may be fused with an aromatic or saturated carbocycle having 1 to 10 carbon atoms,
- R3 is hydrogen, halogen, straight-chain or branched alkyl, straight-chain or branched halogenoalkyl, straight-chain or branched alkoxy, or alkoxycarbonyl having in each case up to 4 carbon atoms, or CN, NO2 or NR19R20,
- in which
- R19 and R20 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- m is an integer from 1 to 4,
- W is straight-chain or branched alkylene having up to 6 carbon atoms or straight-chain or branched alkenediyl having up to 6 carbon atoms, which may in each case contain a group selected from the group consisting of O, S(O)q, NR21, CO and CONR21, or is CO, NHCO or OCO,
- in which
- q is 0, 1 or 2,
- R21 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- U is straight-chain or branched alkyl having up to 4 carbon atoms,
- A is aryl having 6 to 10 carbon atoms, which may optionally be mono- to trisubstituted by halogen, straight-chain or branched alkyl, straight-chain or branched halogenoalkyl, straight-chain or branched alkoxy, halogenoalkoxy or alkoxycarbonyl having up to 4 carbon atoms, CN, NO2 or NR22R23,
- in which
- R22 and R23 independently of one another are each hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, carbonylalkyl or sulphonylalkyl,
- R2 is COOR24 or CONR25R26,
- in which
- R24 is hydrogen, alkyl having 1 to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R25 and R26 independently of one another are each hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO2R27,
- in which
- R27 is straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, CN, NO2, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms,
- X is straight-chain or branched alkylene having up to 12 carbon atoms or straight-chain or branched alkenediyl having up to 12 carbon atoms which may in each case contain one to three groups selected from the group consisting of O, S(O)r, NR28, CO and CONR29, or is aryl or aryloxy having 6 to 10 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, CN, NO2, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms, where optionally any two atoms of the abovementioned chains are attached to one another via an alkyl chain, forming a three- to eight-membered ring,
- in which
- r is 0, 1 or 2,
- R28 is hydrogen, alkyl having 1 to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R29 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- n is 1 or 2;
- and
- R1 is COOR30 or CONR31R32,
- in which
- R30 is hydrogen, alkyl having 1 to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R31 and R32 independently of one another are each hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO2R33,
- in which
- R33 is straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, where the aryl radical for its part may be mono- or polysubstituted by halogen, CN, NO2, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy having up to 6 carbon atoms,
- or a stereoisomer or pharmaceutically acceptable salt thereof.
A method of treating a cardiovascular disorder, comprising administering to a mammal an effective amount of a compound which is capable of stimulating soluble guanylate cyclase independently of the haem group in the enzyme.
A method of treating arteriosclerosis, hypertension, thromboembolic disorders, venous disorders, or fibrotic disorders, comprising administering to a mammal an effective amount of a compound which is capable of stimulating soluble guanylate cyclase independently of the haem group in the enzyme.
Dependencies are inferred from the claim text.